Bao Quan-Lei, Li Jian, Sun Wei, Jiang He-Guo, Zhu Li-Rong, Wang Yi
Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang.
Department of Pulmonary Medicine, Affiliated Hospital of Jiangsu University, Zhenjiang
Jpn J Clin Oncol. 2014 Dec;44(12):1198-205. doi: 10.1093/jjco/hyu141. Epub 2014 Oct 1.
The purpose of this study was to evaluate the diagnostic utility of lung-specific X protein (LUNX) mRNA and vascular endothelial growth factor mRNA in differentiating pleural effusion of different origin.
A total of 136 patients with pleural effusion (46 cases of malignant pleural effusion caused by lung cancer, 30 cases of malignant pleural effusion caused by other cancers and 60 cases of benign pleural effusion) were enrolled in this study. Levels of LUNX mRNA and vascular endothelial growth factor mRNA in pleural fluid were detected by real-time quantitative polymerase chain reaction. Pleural fluid carcinoembryonic antigen and Cyfra21-1 were also measured simultaneously.
The LUNX mRNA level was significantly higher in malignant pleural effusion caused by lung cancer than in malignant pleural effusion caused by other cancers and in benign pleural effusion. In malignant pleural effusion caused by cancers of different origin, the vascular endothelial growth factor mRNA level was significantly higher than in benign pleural effusion. For the diagnosis of malignant pleural effusion caused by lung cancer, LUNX mRNA exhibited higher sensitivity (80%), when compared with vascular endothelial growth factor mRNA (65%), carcinoembryonic antigen (67%) and Cyfra21-1 (61%), with the same specificity (95%). The combination of LUNX mRNA and cytology achieved a sensitivity of 85%. The combined use of LUNX mRNA and vascular endothelial growth factor mRNA and cytology raised the sensitivity to 89%, with 95% specificity. In initial cytology-negative pleural effusion from lung cancer, LUNX mRNA achieved the highest positive result (65%) among the four markers.
The detection of LUNX mRNA and vascular endothelial growth factor mRNA in pleural fluid may be a complementary tool for the diagnosis of malignant pleural effusion. In particular, pleural fluid LUNX mRNA provided a valuable adjunct in distinguishing malignant pleural effusion caused by lung cancer from benign pleural effusion.
本研究旨在评估肺特异性X蛋白(LUNX)mRNA和血管内皮生长因子mRNA在鉴别不同来源胸腔积液中的诊断价值。
本研究共纳入136例胸腔积液患者(46例肺癌所致恶性胸腔积液、30例其他癌症所致恶性胸腔积液和60例良性胸腔积液)。采用实时定量聚合酶链反应检测胸腔积液中LUNX mRNA和血管内皮生长因子mRNA水平。同时检测胸腔积液癌胚抗原和细胞角蛋白19片段。
肺癌所致恶性胸腔积液中LUNX mRNA水平显著高于其他癌症所致恶性胸腔积液和良性胸腔积液。在不同来源癌症所致恶性胸腔积液中,血管内皮生长因子mRNA水平显著高于良性胸腔积液。对于肺癌所致恶性胸腔积液的诊断,LUNX mRNA的敏感性较高(80%),高于血管内皮生长因子mRNA(65%)、癌胚抗原(67%)和细胞角蛋白19片段(61%),特异性相同(95%)。LUNX mRNA与细胞学检查联合使用的敏感性为85%。LUNX mRNA、血管内皮生长因子mRNA与细胞学检查联合使用可将敏感性提高至89%,特异性为95%。在肺癌初诊细胞学阴性的胸腔积液中,LUNX mRNA在四种标志物中阳性结果最高(65%)。
检测胸腔积液中LUNX mRNA和血管内皮生长因子mRNA可能是诊断恶性胸腔积液的一种辅助手段。特别是,胸腔积液LUNX mRNA在鉴别肺癌所致恶性胸腔积液与良性胸腔积液方面提供了有价值的辅助诊断依据。